BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 996 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 996 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $349.17, for a total transaction of $347,773.32. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, October 8th, Chan Henry Lee sold 10,671 shares of BeOne Medicines stock. The stock was sold at an average price of $350.40, for a total transaction of $3,739,118.40.
• On Wednesday, September 10th, Chan Henry Lee sold 10,006 shares of BeOne Medicines stock. The shares were sold at an average price of $325.53, for a total value of $3,257,253.18.

BeOne Medicines Trading Down 0.7%

ONC stock traded down $2.54 on Friday, reaching $365.82. The company’s stock had a trading volume of 230,040 shares, compared to its average volume of 257,949. The firm has a market cap of $40.12 billion, a PE ratio of 717.29 and a beta of 0.31. The business has a fifty day simple moving average of $329.90 and a two-hundred day simple moving average of $291.46. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $170.99 and a 12-month high of $381.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39.

Analyst Upgrades and Downgrades

ONC has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Citigroup lifted their price target on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Royal Bank Of Canada increased their price objective on BeOne Medicines from $374.00 to $395.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, Barclays assumed coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They set an “overweight” rating and a $385.00 target price on the stock. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $357.33.

Institutional Trading of BeOne Medicines

A number of large investors have recently made changes to their positions in ONC. Parallel Advisors LLC bought a new position in BeOne Medicines during the second quarter valued at approximately $59,000. Aaron Wealth Advisors LLC bought a new position in shares of BeOne Medicines during the 2nd quarter valued at $200,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines in the second quarter worth $39,000. Avanza Fonder AB purchased a new stake in BeOne Medicines during the second quarter valued at $199,000. Finally, Public Employees Retirement System of Ohio bought a new position in BeOne Medicines in the second quarter valued at about $3,491,000. 48.55% of the stock is currently owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.